STRATEGIC ADVISING FOR
Health systems, academic medical centers and biopharma organizations constantly seek to develop life-changing precision medicine and population genomics programs. However, many institutions face uncertainty about how to begin, lack dedicated resources, and are uncertain about how to scale their programs, oftentimes risking costly delays or even program failure.Learn moreChat with us
Design, Develop and
Accelerate Your Program
Today's rapidly-changing health care and clinical study landscape requires efficiency, agility and long-term foresight. The road is rarely linear. We will work with you to design the path forward that is best for you.
Genome Medical’s evidence-informed approach considers all facets of the genomics and/or precision medicine program and is optimized for scaling, sustainability and success with a focus on a quality patient journey.
As pioneers in this space, the Precision Insights team provides expertise, focus and proven best-practices, to accelerate internal decision-making and drive the design, development and launch of research, clinical and population-scale genomic programs.Request infoChat with us
Much More Than
The Precision Insights team provides in-depth domain expertise and guidance in addition to evidence-based deliverables, including patient and provider educational content, and clinical research study support, including IRB protocol development.
Precision Insights provides expertise and support to a diverse group of partners, including health systems, laboratories, health care service organizations, biopharmaceutical, and biotech companies.
OUR EXPERT ADVISORS HELP YOUR ORGANIZATION TO:
- Adopt best practices that create alignment
- Anticipate and avoid common implementation challenges that lead to delay or failure
- Move quickly through all phases of the program journey — from initial planning and engagement to long-term support, management and beyond
Our methods enable and support partners, empowering and accelerating their ability to drive program success through concept, design, launch and ongoing implementation.
LEADER ENGAGEMENT & FEASIBILITY
Engagement strategies, capacity assessment and gap analysis to ensure feasibility and alignment
Program design, including IRB protocol development and patient and provider educational strategies and content
Clinical pathway recommendations including return of results and longitudinal care navigation
Structure system-specific value and outcomes assessments and scaling strategies
Meet Our Experts
Our professionals guide your precision medicine program towards success and reaching its full potential.
Hunt Willard, PhD
Hunt has deep experience in genetics and genomics leadership in academia, health care and industry, building teams that span research, education and clinical care. Prior to joining Genome Medical, he was most recently director and principal of National Precision Health at Geisinger Health in Maryland and Pennsylvania, with a focus on design and implementation of large-scale clinical and research programs in genomics and population screening. He is the author or co-author of more than 350 scientific publications, co-editor of the Genomic and Precision Medicine book series and a longtime co-author of the textbook Genetics in Medicine. A former president of the American Society of Human Genetics, he is an elected member of the National Academy of Medicine and the National Academy of Sciences.
Erica Ramos, MS, CGC
Erica is the vice president of population genomics at Genome Medical. She is responsible for developing the strategy, value proposition and overall approach to population-scale health initiatives utilizing genetics and genomics and is passionate about establishing genomics as a resource for life-long care and integrating broad-based screening approaches with indication-based diagnostic services. In her previous role as director of clinical and product development at Geisinger National Precision Health, she and her team developed and integrated scalable, efficient and innovative clinical programs and products to accelerate the responsible adoption and integration of genomics into preventive care and population health. Prior to joining Geisinger, Erica was an associate director of market development for Precision Health and Screening at Illumina and practiced as a clinical genetic counselor for 11 years. Erica is a nationally recognized leader in the genetic counseling community, serving as the 2018 president of the National Society of Genetic Counselors, the leading professional organization for genetic counselors, more than 4,000 members strong, and serving on the All of Us Research Program Advisory Panel. She is also an adjunct professor in the Genetic Counseling Department at Augustana University and shares her enthusiasm for genomics, genetic counseling and Wisconsin sports on Twitter at @ERamosSD.
Beth Denne, MS, CGC
Beth is a board-certified and licensed genetic counselor, practicing since 2000. A leader in the genetic counseling community, Beth has served as president of the American Board of Genetic Counseling and on several committees for the National Society of Genetic Counselors. Prior to joining Genome Medical, Beth was the genetic counseling and education program leader for Geisinger National Precision Health. She previously served as director of genetic counseling services for Counsyl, Inc. During her seven years at Counsyl, she helped to develop and build the genetic counseling service, which incorporated new technologies and alternative service delivery models for telegenetic counseling into standard practice. Beth spent the first 12 years of her career at Johns Hopkins University Hospital as a Gyn/Ob faculty member in the Department of Maternal-Fetal Medicine.
Molly McGinniss, MS, CGC
Molly is a board-certified genetic counselor with extensive clinical and commercial expertise. She joined Genome Medical from Illumina, where she held market development roles focused on expansion of sequencing applications into emerging clinical markets through evidence generation and strategic partnerships. Molly began her career as a clinical genetic counselor providing prenatal, pediatric and adult genetic counseling services and has served on the Board of Directors for the Accreditation Council for Genetic Counseling (ACGC) since 2018 and has held additional leadership roles for the National Society of Genetic Counselors (NSGC). She received her Bachelor’s degree from Loyola Marymount University and her Masters in Genetic Counseling from the Boston University School of Medicine.
Jenna Petersen, MS, CGC
Jenna is a board-certified genetic counselor experienced in developing innovative and engaging content for large genomics projects. She is passionate about increasing access to genetic counseling and testing through scalable approaches to education and service delivery. Jenna joined Genome Medical from AncestryDNA, where she provided clinical expertise for the development of consumer-initiated genetic health products.
Katelyn Swade, MS, CGC
Katelyn is a board-certified genetic counselor specializing in cardiac genetics. She established an adult cardiac genetics program at the University of Utah. In this role, she provided genetic counseling for patients with hypertrophic cardiomyopathy, familial hypercholesterolemia, cardiac amyloidosis and other adult-onset cardiac conditions.
Ready to learn more?
Let's Accelerate Your
Precision Medicine Program
DOWNLOAD CASE STUDY
Precision Insights Services
Accelerate Program Launch
A large health system was struggling to move past the planning phase of a precision medicine program. Learn how our Precision Insights Services helped to accelerate and launch the program in 8 months.
The Latest from Our Experts
2021 was a pivotal year for advances in genomic medicine. Our industry at large is primed with new testing capabilities and novel therapeutics on the brink of entering the market – now is the time to deliver expanded availability of genomic medicine for all.
Precision medicine is a common term used in health care. But what does it mean? Learn more about what precision medicine is, what it is not and how this approach to medical care can be valuable to individuals, families and health systems when paired with clinical experts in genomic medicine.